These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 12051463

  • 1. The immunopathogenesis of multiple sclerosis.
    Prat E, Martin R.
    J Rehabil Res Dev; 2002; 39(2):187-99. PubMed ID: 12051463
    [Abstract] [Full Text] [Related]

  • 2. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP.
    Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
    [Abstract] [Full Text] [Related]

  • 3. The immunopathogenesis of multiple sclerosis. A survey of recent advances and implications for future therapy.
    Kieseier BC, Archelos JJ, Storch M, Gold R, Hartung HP.
    Wien Klin Wochenschr; 1999 Sep 17; 111(17):728-37. PubMed ID: 10526397
    [Abstract] [Full Text] [Related]

  • 4. The immunological basis for treatment of multiple sclerosis.
    Holmøy T, Vartdal F.
    Scand J Immunol; 2007 Oct 17; 66(4):374-82. PubMed ID: 17850581
    [Abstract] [Full Text] [Related]

  • 5. The immunopathogenesis of multiple sclerosis.
    Giovannoni G.
    Baillieres Clin Neurol; 1997 Oct 17; 6(3):387-407. PubMed ID: 10101580
    [Abstract] [Full Text] [Related]

  • 6. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
    Karussis D, Slavin S.
    J Neurol Sci; 2004 Aug 15; 223(1):59-64. PubMed ID: 15261562
    [Abstract] [Full Text] [Related]

  • 7. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease.
    Bomprezzi R, Ringnér M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM.
    Hum Mol Genet; 2003 Sep 01; 12(17):2191-9. PubMed ID: 12915464
    [Abstract] [Full Text] [Related]

  • 8. Immunotherapy of multiple sclerosis.
    Weiner HL, Hafler DA.
    Ann Neurol; 1988 Mar 01; 23(3):211-22. PubMed ID: 3288084
    [Abstract] [Full Text] [Related]

  • 9. Multiple sclerosis: an immunologic perspective.
    Cui JY.
    Phys Med Rehabil Clin N Am; 2005 May 01; 16(2):351-8. PubMed ID: 15893676
    [Abstract] [Full Text] [Related]

  • 10. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
    Fontoura P, Garren H, Steinman L.
    Int Rev Immunol; 2005 May 01; 24(5-6):415-46. PubMed ID: 16318989
    [Abstract] [Full Text] [Related]

  • 11. The spectrum of multiple sclerosis and treatment decisions.
    Siva A.
    Clin Neurol Neurosurg; 2006 Mar 01; 108(3):333-8. PubMed ID: 16378680
    [Abstract] [Full Text] [Related]

  • 12. Overview of the rationale for immunomodulating therapies in multiple sclerosis.
    Lisak RP.
    Neurology; 1988 Jul 01; 38(7 Suppl 2):5-8. PubMed ID: 3290714
    [Abstract] [Full Text] [Related]

  • 13. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?
    Weiner HL.
    Ann Neurol; 2009 Mar 01; 65(3):239-48. PubMed ID: 19334069
    [Abstract] [Full Text] [Related]

  • 14. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
    Holmøy T.
    Minerva Med; 2008 Apr 01; 99(2):119-40. PubMed ID: 18431322
    [Abstract] [Full Text] [Related]

  • 15. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET, Giovannoni G.
    Expert Rev Neurother; 2005 May 01; 5(3):379-90. PubMed ID: 15938671
    [Abstract] [Full Text] [Related]

  • 16. [Multiple sclerosis: a multi-specific immune deficiency disease].
    Lamoureux G, Toupin J, Leyva F.
    Ann Immunol (Paris); 1977 May 01; 128(1-2):531-6. PubMed ID: 848902
    [Abstract] [Full Text] [Related]

  • 17. T cell gene expression profiling identifies distinct subgroups of Japanese multiple sclerosis patients.
    Satoh J, Nakanishi M, Koike F, Onoue H, Aranami T, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, Ota K, Saito T, Ohta M, Miyake S, Kanda T, Fukazawa T, Yamamura T.
    J Neuroimmunol; 2006 May 01; 174(1-2):108-18. PubMed ID: 16564577
    [Abstract] [Full Text] [Related]

  • 18. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
    Wiendl H, Feger U, Mittelbronn M, Jack C, Schreiner B, Stadelmann C, Antel J, Brueck W, Meyermann R, Bar-Or A, Kieseier BC, Weller M.
    Brain; 2005 Nov 01; 128(Pt 11):2689-704. PubMed ID: 16123145
    [Abstract] [Full Text] [Related]

  • 19. Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy.
    Vaknin-Dembinsky A, Weiner HL.
    J Neurol Sci; 2007 Aug 15; 259(1-2):90-4. PubMed ID: 17521671
    [Abstract] [Full Text] [Related]

  • 20. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?
    Friese MA, Fugger L.
    Brain; 2005 Aug 15; 128(Pt 8):1747-63. PubMed ID: 15975943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.